Gilead Sciences : Cyprus EFPIA Report 2024 (In English) (gilead sciences efpia report 2024 in english cyprus)

Published: 2025-06-26 08:23:09 ET GILD

Published on 06/26/2025 at 08:23

Date of Publication:30/6/2025

Full Name

(Άρθρο 1.01)

HCPs: City of Principal Practice

HCOs: city where registered

(Άρθρο 3)

Country of Principal Practice

(Παράρτημα 1)

Principal Practice Address

(Άρθρο 3)

Donations and Grants to HCOs(άρθρο 3.01.1.α)

Contribution to costs of Events (Άρθρα 3.01.1.β & 3.01.2.α)

Fee for service and consultancy (Άρθρα.

3.01.1.γ & 3.01.2.β)

Total Optional

Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an Event

Registration Fees

Travel &

Accommodation

Fees

Related expenses agreed in the fee for service or consultancy contract,

including travel &

accommodation relevant to the contract

ΑΤΟΜΙΚΑ

HCPs

INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)

OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons

Aggregate amount attributable to transfers of value to such Recipients

274,20 4688,08 2805,00 0,00

7.767,28 €

Number of Recipients in aggregate disclosure

7,00 €

% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed

100%

HCOs

INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)

ΚΥΠΡ.ΕΤ.ΚΛΙΝ.ΜΙΚΡΟΒ.& ΛΟΙΜΩΞΕΩΝ

Λευκωσια

Cyprus

ΘΑΣΟΥ 14

0,00

11200,00

0,00

11200,00

ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΥΠΡΟΥ

Λευκωσία

Cyprus

Λεωφ. Πανεπιστημίου 1, Αγλαντζιά

0,00

1227,69

0,00

1227,69

OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons

Aggregate amount attributable to transfers of value to such Recipients

Number of Recipients in aggregate disclosure

% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed

AGGREGATE DISCLOSURE

Transfers of Value re Research & Development as defined

0,00

R&D

Page 1

Disclaimer

Gilead Sciences Inc. published this content on June 26, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 26, 2025 at 12:22 UTC.